Literature DB >> 9350289

Interferon-gamma-induced MHC class I expression and defects in Jak/Stat signalling in methylcholanthrene-induced sarcomas.

I M Svane1, A M Engel, M Nielsen, O Werdelin.   

Abstract

Seventy-eight uncloned tumour cell lines, each established from a primary sarcoma induced with methyl-cholanthrene in immunocompetent nu/+ BALB/c and C.B.-17 mice or in immunodeficient nu/nu BALB/c and severe combined immunodeficient (SCID) mice, were examined for sensitivity to interferon-gamma (IFN-gamma) as measured by tumour cell augmentation of major histocompatibility complex (MHC) class I expression. The tumour cells were cultured with IFN-gamma and their expression of Kd, Dd and Ld was measured by fluorescence-activated cell sorter analysis. All but three of the 78 tumour lines up-regulated Kd, Dd and Ld to a variable degree in response to IFN-gamma, indicating that IFN-gamma resistance is not a common property of these sarcomas. The tumour cell lines varied greatly in their MHC class I expression before as well as after IFN-gamma stimulation. There was a tendency towards a higher MHC expression after IFN-gamma stimulation in tumour lines from immunocompetent mice compared to immunodeficient mice, but no common maximum MHC class I expression level was found for the 78 tumour cell lines. Three of the tumour lines, all from immunodeficient mice, completely failed to respond to IFN-gamma by up-regulating MHC class I expression. The same three also displayed absence of IFN-gamma-induced Stat1 beta tyrosine phosphorylation and low Stat1 alpha tyrosine phosphorylation, indicating a defect in the signal transduction pathway affecting phosphorylation of Stat1. These findings strongly suggest a link between defects in Stat1 phosphorylation and the failure to up-regulate MHC class I. In all tumour lines tested, the Stat1 Western blotting revealed a 78 kDa protein (p78) not previously described.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9350289     DOI: 10.1046/j.1365-3083.1997.d01-141.x

Source DB:  PubMed          Journal:  Scand J Immunol        ISSN: 0300-9475            Impact factor:   3.487


  7 in total

1.  CD8+ T cells are crucial for the ability of congenic normal mice to reject highly immunogenic sarcomas induced in nude mice with 3-methylcholanthrene.

Authors:  M Boesen; I M Svane; A M Engel; J Rygaard; A R Thomsen; O Werdelin
Journal:  Clin Exp Immunol       Date:  2000-08       Impact factor: 4.330

Review 2.  The role of cytotoxic T-lymphocytes in the prevention and immune surveillance of tumors--lessons from normal and immunodeficient mice.

Authors:  I M Svane; M Boesen; A M Engel
Journal:  Med Oncol       Date:  1999-12       Impact factor: 3.064

Review 3.  Cell Signaling Pathways That Regulate Antigen Presentation.

Authors:  Randy R Brutkiewicz
Journal:  J Immunol       Date:  2016-10-15       Impact factor: 5.422

4.  Evolutional change of karyotype with t(8;9)(p22;p24) and HLA-DR immunophenotype in relapsed acute myeloid leukemia.

Authors:  Kuan-Po Huang; Andrew J Chase; Nicholas C P Cross; Andrea Reiter; Tzu-Ying Li; Tso-Fu Wang; Sung-Chao Chu; Xuan-Yin Lu; Chi-Cheng Li; Ruey-Ho Kao
Journal:  Int J Hematol       Date:  2008-07-02       Impact factor: 2.490

Review 5.  The cholesterol pathway: impact on immunity and cancer.

Authors:  Ryan J King; Pankaj K Singh; Kamiya Mehla
Journal:  Trends Immunol       Date:  2022-01       Impact factor: 16.687

Review 6.  Inflammatory cytokines: potential biomarkers of immunologic dysfunction in autism spectrum disorders.

Authors:  Ningan Xu; Xiaohong Li; Yan Zhong
Journal:  Mediators Inflamm       Date:  2015-02-01       Impact factor: 4.711

7.  CXCL16-positive dendritic cells enhance invariant natural killer T cell-dependent IFNγ production and tumor control.

Authors:  Linnea Veinotte; Simon Gebremeskel; Brent Johnston
Journal:  Oncoimmunology       Date:  2016-04-22       Impact factor: 8.110

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.